The relationship between psychosomatic features and indicators of liver function and body mass index in patients with hypothyroidism and their dynamics against the background of comprehensive treatment | Ukrainian Medical Journal

Sirchak Ye.S.,Voloshin M.M.,Arhij E.Yo.,Lemko I.I.,Kurica A.M.,Petrichko O.I.,Popovich S.S.

Main
Publications
The relationship between psychosomatic features and indicators of liver function and body mass index in patients with hypothyroidism and their dynamics against the background of comprehensive treatment

The relationship between psychosomatic features and indicators of liver function and body mass index in patients with hypothyroidism and their dynamics against the background of comprehensive treatment

April 14, 2026

242

УДК: 616.441-008.64:616.36-008:616-056.257-071.3:616.89]-036-08

DOI: 10.32471/umj.1680-3051.275218

Keywords :

magnesium bisglycinate,

melatonin,

metabolic-associated fatty liver disease,

obesity,

probiotic,

psychosomatic changes,

ursodeoxycholic acid,

vitamin B6

Specialities :

Endocrinology

Hepatology

Resume

The study of psychosomatic changes in patients with hypothyroidism (HT) and metabolic-associated fatty liver disease (MAFLD), as well as their progression during treatment, is a pressing issue in the study of comorbid conditions. The aim of the study: to investigate the psychosomatic characteristics of patients with HT combined with MAFLD and obesity, as well as their dynamics during comprehensive treatment involving hepatoprotective drugs and probiotics. Materials and methods. At the clinical center of the Department of Propaedeutics of Internal Medicine, 126 patients with HT and obesity combined with MAFLD were examined. The patients were divided into two clinical groups based on their treatment method. Group 1 included 76 patients who received only basic therapy, which consisted of levothyroxine combined with ursodeoxycholic acid (UDCA) for 3 months. Group 2 consisted of 50 patients who, in addition to basic therapy, received a preparation containing magnesium, vitamin B6, melatonin, and a probiotic complex for 3 months. Results. Up to 70.0% of patients with HT combined with MAFLD and obesity of varying severity exhibit difficulties in verbalizing their own emotions, as indicated by the results of the Toronto Alexithymia Scale. Results of the Zung scale indicate a severe form of depression in more than half of the examined patients with HT and impaired liver function combined with obesity. Test results on the MMSE, MoCA, and «Draw a Clock» scales indicate cognitive deficits in the examined patients. Conclusions. Patients with HT, MAFLD and obesity exhibited signs of depression, predominantly of moderate severity, as well as manifestations of cognitive impairment, which depended on liver function, the degree of steatosis, liver fibrosis, the severity of obesity, and insulin resistance in these patients. Complex therapy using UDCA, a preparation containing melatonin, magnesium bisglycinate, and vitamin B6 in combination with a probiotic is an effective method for correcting signs of depression and cognitive impairment in patients with HT combined with MAFLD and obesity.

References

1. Yorke E. (2024) Co-Morbid Hypothyroidism and Liver Dysfunction: A Review. Clin. Med. Insights Endocrinol. Diabetes, 17: 11795514241231533.
2. Shahid M.A., Ashraf M.A., Sharma S. (2023) Physiology, Thyroid Hormone. In: StatPearls. Treasure Island (FL): StatPearls Publ.
3. He W., An X., Li L. et al. (2017) Relationship between Hypothyroidism and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. Front. Endocrinol. (Lausanne), 8: 335. doi: 10.3389/fendo.2017.00335.
4. Guo Z., Li M., Han B., Qi X. (2018) Association of non-alcoholic fatty liver disease with thyroid function: A systematic review and meta-analysis. Dig. Liver Dis., 50(11): 1153–1162. doi: 10.1016/j.dld.2018.08.012.
5. Beukhof C.M., Massolt E.T., Visser T.J. et al. (2018) Effects of Thyrotropin on Peripheral Thyroid Hormone Metabolism and Serum Lipids. Thyroid, 28(2): 168–174.
6. Langén V.L., Niiranen T.J., Puukka P. et al. (2017) Association of thyroid-stimulating hormone with lipid concentrations: an 11-year longitudinal study. Clin. Endocrinol. (Oxf.), 86(1): 120–127. doi: 10.1111/cen.13151.
7. Yan F., Wang Q., Lu M. et al. (2014) Thyrotropin increases hepatic triglyceride content through upregulation of SREBP-1c activity. J. Hepatol., 61(6): 1358–1364.
8. Yorke E. (2022) Hyperthyroidism and Liver Dysfunction: A Review of a Common Comorbidity. Clin. Med. Insights. Endocrinol. Diabetes, 15: 11795514221074672.
9. Huang X., Zhang H., Qu C. et al. (2019) Depression and Insomnia Are Closely Associated with Thyroid Hormone Levels in Chronic Hepatitis B. Med. Sci. Monit., 25: 2672–2678. doi: 10.12659/MSM.914444.
10. Mantovani A., Grani G. (2018) Thyroid Dysfunction and Nonalcoholic Fatty Liver Disease: We Need New Larger and Well-Designed Longitudinal Studies. Dig. Dis. Sci., 63(7): 1970–1976. doi: 10.1007/s10620-018-5075-7.
11. Wu Y., You S., Zang H. et al. (2015) Usefulness of serum thyroid-stimulation hormone (TSH) as a prognostic indicator for acute-on-chronic liver failure. Ann. Hepatol., 14(2): 218–224.
12. Moylan S., Maes M., Wray N.R., Berk M. (2013) The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications. Mol. Psychiatr., 18(5): 595–606. doi: 10.1038/mp.2012.33.
13. Gao J., Xu W., Han K. et al. (2017) Changes of serum uric acid and total bilirubin in elderly patients with major postischemic stroke depression. Neuropsychiatr. Dis. Treat., 14: 83–93. doi: 10.2147/NDT.S149712.
14. Peng Y.F., Xiang Y., Wei Y.S. (2016) The significance of routine biochemical markers in patients with major depressive disorder. Sci. Rep., 6: 34402.
15. Saleh K., Javaheri S. (2018) Sleep in ambulatory patients with stable cirrhosis of the liver. Sleep Med., 41: 15–19. doi: 10.1016/j.sleep.2017.08.022.